Omaxe Limited has reported its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, following the Board of Directors meeting held on May 15, 2026. The results, approved under Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, reveal a widening net loss and a significant decline in revenue on a year-on-year basis across both standalone and consolidated financials. Statutory auditor M/s B S D & Co., Chartered Accountants (FRN: 000312S), issued unmodified audit opinions on both the standalone and consolidated financial results. The results were subsequently published in Business Standard (English and Hindi) on May 15, 2026, in compliance with Regulation 47 of the SEBI LODR Regulations, 2015.

Q4 FY26 and Full-Year Financial Performance

Omaxe's consolidated financials for Q4 FY26 showed deterioration across key metrics compared to the same period last year. On a consolidated basis, revenue from operations for Q4 FY26 declined to ₹348.52 Cr from ₹541.26 Cr in Q4 FY25. The consolidated net loss after tax for Q4 FY26 stood at ₹191.42 Cr, compared to ₹148.67 Cr in Q4 FY25. For the full year FY26, consolidated revenue from operations stood at ₹1,253.40 Cr, down from ₹1,560.99 Cr in FY25, while the consolidated net loss after tax widened to ₹696.80 Cr from ₹685.40 Cr in FY25.

The table below summarises the key consolidated financial highlights:

Standalone Financial Performance

On a standalone basis, Omaxe's Q4 FY26 total income rose to ₹168.49 Cr from ₹150.47 Cr in Q4 FY25. However, the standalone net loss after tax for Q4 FY26 widened significantly to ₹83.05 Cr from ₹20.76 Cr in Q4 FY25, driven by a sharp increase in total expenses to ₹278.81 Cr from ₹170.35 Cr. For the full year FY26, standalone total income grew to ₹514.67 Cr from ₹449.97 Cr in FY25, while the standalone net loss after tax narrowed to ₹195.61 Cr from ₹217.03 Cr in FY25.

Balance Sheet and Cash Flow Highlights

As of March 31, 2026, Omaxe's consolidated total assets stood at ₹16,522.32 Cr, up from ₹14,877.41 Cr as of March 31, 2025, driven primarily by a significant increase in consolidated inventories to ₹12,315.85 Cr from ₹10,997.66 Cr. Consolidated cash and cash equivalents improved to ₹490.38 Cr from ₹300.93 Cr. On the liabilities side, consolidated non-current borrowings rose sharply to ₹1,267.07 Cr from ₹499.24 Cr, while consolidated other equity turned more negative at ₹(1,084.42) Cr compared to ₹(388.03) Cr in the prior year. On a standalone basis, total assets grew to ₹6,829.84 Cr from ₹6,290.30 Cr, with standalone cash and cash equivalents improving to ₹128.54 Cr from ₹25.20 Cr.

From a cash flow perspective, consolidated net cash generated from operating activities for FY26 stood at ₹211.99 Cr, compared to ₹1,006.67 Cr in FY25. Standalone net cash from operating activities was ₹426.82 Cr versus ₹585.32 Cr in FY25.

Board Decisions and Auditor Appointments

At the Board meeting held on May 15, 2026, in addition to approving the financial results, the Board also approved the appointment of M/s S.K. Bhatt & Associates, Cost Accountants, as Cost Auditors for FY26-27, and the appointment of M/s Aditya V Agarwal & Company, Chartered Accountants, as Internal Auditors for FY26-27, replacing M/s Doogar & Associates, who resigned due to pre-occupation with other assignments. Both new appointments are effective May 15, 2026. The Board also noted proposed final dividends from certain wholly owned subsidiaries, subject to approval at their respective general meetings, as detailed below:

Regulatory and Legal Disclosures

The auditors drew attention to an ongoing regulatory matter in their Emphasis of Matter paragraph. Omaxe had received an order dated July 30, 2024, from SEBI under sections 11 and 11B of the SEBI Act, 1992, covering the period from FY2018-19 to FY2020-21. The company filed an appeal with the Securities Appellate Tribunal (SAT), which granted a stay on directions at para 41(i) of the SEBI order vide its order dated October 1, 2024. The next date of hearing before SAT is July 7, 2026. The management has stated that the said order has no impact on the financial results of the company. Separately, Omaxe confirmed that as of March 31, 2026, it does not qualify as a "Large Corporate" under the relevant SEBI circulars on fund raising by issuance of debt securities. The company's outstanding qualified borrowings stood at ₹414.08 Cr at year-end, up from ₹178.39 Cr at the start of the financial year, with incremental borrowings of ₹200 Cr and debt securities issuance of ₹63.30 Cr during the year. The company holds a credit rating of ACUITE BBB- (Stable) from Acuite Ratings & Research Limited.

Omaxe Limited has disclosed, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, that its wholly-owned subsidiary, M/s Omaxe Garv Buildtech Private Limited, has received RERA Registration Certificates for two of its commercial projects from the Uttar Pradesh Real Estate Regulatory Authority (U.P. RERA). The disclosure was made on May 06, 2026, and the project details are available on the U.P. RERA website at www.up-rera.in .

RERA Registrations for Commercial Projects in Lucknow

Both projects — Commercial-3 Block-1 and Commercial-3 Block-2 — are situated at Tehsil Sarojini Nagar, District Lucknow, Uttar Pradesh, and are scheduled for launch on 07-05-2026. The registrations cater to both domestic and international markets. The key details of the two registered projects are presented below:

Regulatory Significance and Impact

The RERA registrations are granted subject to certain standard conditions. According to the company's disclosure, the approvals enable the wholly-owned subsidiary to sell, transfer, or advertise the respective projects. The company has stated that RERA registration certifies compliance with regulations, enhances credibility, ensures timely delivery, and fosters trust with buyers by guaranteeing transparency and legal protection. The registrations are expected to strengthen the brand value and positively impact the consolidated financial performance of Omaxe Limited.

Disclosure Compliance

The intimation has been filed in accordance with Regulation 30 read with Schedule III of the SEBI LODR Regulations, 2015, and the SEBI Master Circular vide Reference No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The disclosure has been signed by D B R Srikanta, Company Secretary & Compliance Officer of Omaxe Limited, and a copy of the intimation has been uploaded on the company's website at www.omaxe.com as well as on the websites of the concerned stock exchanges.